Danaher (NYSE:DHR) Announces Earnings Results, Beats Expectations By $0.26 EPS

Danaher (NYSE:DHR - Get Free Report) released its quarterly earnings results on Tuesday. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.26, Zacks reports. The company had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a net margin of 16.33% and a return on equity of 10.82%. Danaher updated its FY 2025 guidance to 7.600-7.750 EPS.

Danaher Trading Down 0.6 %

Danaher stock traded down $1.25 during mid-day trading on Friday, hitting $195.25. The company's stock had a trading volume of 169,218 shares, compared to its average volume of 3,341,432. The stock has a market cap of $139.55 billion, a PE ratio of 36.89, a P/E/G ratio of 2.66 and a beta of 0.86. Danaher has a one year low of $171.00 and a one year high of $281.70. The company has a 50 day moving average of $201.01 and a 200-day moving average of $225.07. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a dividend of $0.32 per share. This is a positive change from Danaher's previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date of this dividend is Friday, March 28th. Danaher's dividend payout ratio (DPR) is currently 24.85%.

Wall Street Analyst Weigh In

DHR has been the topic of a number of recent research reports. Raymond James reaffirmed a "market perform" rating on shares of Danaher in a research report on Monday, February 3rd. Jefferies Financial Group cut their price target on Danaher from $260.00 to $230.00 and set a "buy" rating on the stock in a research note on Tuesday. The Goldman Sachs Group dropped their price target on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a research note on Wednesday. Stifel Nicolaus upgraded shares of Danaher from a "hold" rating to a "buy" rating and set a $260.00 target price on the stock in a research note on Friday, March 14th. Finally, Wells Fargo & Company reduced their price target on shares of Danaher from $280.00 to $240.00 and set an "equal weight" rating for the company in a research report on Thursday, January 30th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $264.40.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 5,700 shares of the business's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 11.10% of the stock is currently owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.